Biaxin News
Biaxin Litigation: Sandoz' Motion for Stay Pending Appeal Denied ... - Patently-O
all 2 news articles
Popular OTC Medications Get a Boost with FLAVORx's Newest Product ... - FinanceVisor.com (press release)
While many more taste-challenged prescription medications such as Augmentin, Biaxin, Zithromax, Amoxicillin and Cleocin will still require specialized ...
Ipsen Appoints Sean McKercher as Vice President of Commercial ... - PharmaLive.com (press release)
... Abbott's $2 billion in sales co-promotion agreement with Boehringer Ingelheim, General Manager for Abbott's leading antibiotic Biaxin and most recently ...
Abbott Opens New Biotechnology Manufacturing Facility In Puerto - Pharmaceutical Online (press release)
In addition to producing HUMIRA at the new ABL plant, Abbott also manufactures Biaxin, Depakote and Synthroid in Puerto Rico. ...
Analysis: Street lukewarm on Abbott - United Press International
Biaxin sales hit $224 million while Synthroid brought in $129 million. "Our businesses continue to perform well and our outlook remains strong," said Miles ...
Abbott Reports 15.5 Percent Sales Growth in First Quarter - Earthtimes.org
1Q06 Pharmaceutical Products HUMIRA $289 32.4 $282 62.2 (a) $571 45.6 Depakote $305 33.4 $21 22.2 $326 32.6 Kaletra $117 (2.4) $183 14.5 (b) $300 7.2 Biaxin ...
Abbott sees dip in Q1 earnings - Pharma Times (subscription)
TriCor (fenofibrate), the anti-cholesterol, had an 8.7% sales rise to $223 million, although the macrolide antibiotic Biaxin (clarithromycin) saw a fall of ...
Court Stops Sandoz From Selling Generic Of Abbott's Antibiotic - Seeking Alpha
Abbott earns about $300 million each year in the US from sales of Biaxin XL, an antibiotic used primarily for the treatment of bacterial infections of the ...
Biaxin RSS Feed